Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin

Adv Prostaglandin Thromboxane Leukot Res. 1991:21B:603-6.

Authors

P Lumley¹, R J Keery, K A Wharton, B P White, I S Watts

Affiliation

¹ Department of Peripheral Pharmacology, Glaxo Group Research Ltd., Ware, Hertfordshire, U.K.

PMID: 1825385

No abstract available

Publication types

Comparative Study

MeSH terms

6-Ketoprostaglandin F1 alpha / biosynthesis
Adult
Aspirin / pharmacology*
Biphenyl Compounds / pharmacology*
Dose-Response Relationship, Drug
Epoprostenol / biosynthesis*
Heptanoic Acids / pharmacology*
Humans
Male
Platelet Aggregation / drug effects
Receptors, Prostaglandin / antagonists & inhibitors*
Receptors, Thromboxane
Thromboxane A2 / antagonists & inhibitors*
Thromboxane B2 / blood

Substances

Biphenyl Compounds
Heptanoic Acids
Receptors, Prostaglandin
Receptors, Thromboxane
Thromboxane B2
Thromboxane A2
6-Ketoprostaglandin F1 alpha
Epoprostenol
vapiprost
Aspirin